Last reviewed · How we verify

NCT06205394

Improving The Breast Cancer Care Delivery Model for Sex and Gender Minority Survivors, Intended for SGM Study

Completed Last updated 16 January 2024
What this trial tests

trial testing Non-Interventional Study in Breast Carcinoma in 28 participants. Completed in 15 October 2023.

Timeline
24 August 2022
Primary endpoint
15 October 2023
15 October 2023

Quick facts

Lead sponsorOhio State University Comprehensive Cancer Center
StatusCompleted
Study typeOBSERVATIONAL
Enrollment28
Start date24 August 2022
Primary completion15 October 2023
Estimated completion15 October 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Ohio State University Comprehensive Cancer Center

Who can join

Eligibility, any sex, with Breast Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates Improving the Breast Cancer Care Delivery Model for Sex and Gender Minority (INTENDED for SGM) in identifying the patient, support person and provider barriers to quality care in SGM breast/chest cancer survivors.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Non-Interventional Study

Trials testing the same drug.

Other recruiting trials for Breast Carcinoma

Currently open trials in the same condition.

Other Ohio State University Comprehensive Cancer Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06205394.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing